Evert B. Schimmelpennink
Director · Contineum Therapeutics, Inc.
- 2024
- Jun 26, 2026
- 4
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Evert B. Schimmelpennink files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Daniel S. Lorrain - $1.04M in CTNM purchases and sales in the last 12 months
- Carmine N. Stengone - $401K in CTNM purchases and sales in the last 12 months
- Tim Watkins - $279K in CTNM purchases and sales in the last 12 months
- Shawn Olsson - $261K in LENZ purchases and sales in the last 12 months
- James W. McCollum - $239K in LENZ purchases and sales in the last 12 months
- Daniel R. Chevallard - $114K in LENZ purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Evert B. Schimmelpennink?
Evert B. Schimmelpennink is a corporate insider, tracked as Director of Contineum Therapeutics, Inc. (CTNM). InsiderAlpha holds 4 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Evert B. Schimmelpennink last file a Form 4?
The most recent primary Form 4 on record is dated 26 June 2026, one of 4 filings going back to 2024.
Has Evert B. Schimmelpennink been buying or selling stock?
Recorded transactions: 1 open-market purchase ($251K) and 0 open-market sales across all tracked filings.
